当前位置: X-MOL 学术J. Alzheimer’s Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease.
Journal of Alzheimer’s Disease ( IF 4 ) Pub Date : 2020-07-02 , DOI: 10.3233/jad-200416
Masaaki Waragai 1 , Gilbert Ho 2 , Yoshiki Takamatsu 1 , Ryoko Wada 1 , Shuei Sugama 3 , Takato Takenouchi 4 , Eliezer Masliah 5 , Makoto Hashimoto 1
Affiliation  

Abstract

Despite the apparent neurotoxicity of amyloid-β (Aβ), recent clinical trials of Aβ immunotherapy have not shown any clinical benefit in Alzheimer’s disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in promoting amyloidogenic evolvability in reproduction, which may result in the adiponectin paradox through antagonistic pleiotropy mechanism in aging, leading to AD. Accordingly, preventing the adiponectin paradox by suppressing adiponectin signaling might prove therapeutic in AD.



中文翻译:

脂联素悖论作为阿尔茨海默氏病的治疗靶标。

摘要

尽管淀粉样蛋白-β(Aβ)具有明显的神经毒性,但Aβ免疫疗法的最新临床试验尚未显示出对阿尔茨海默氏病(AD)的任何临床益处。鉴于此,有必要澄清AD中的下一代治疗策略。假设脂联素可能参与促进生殖中淀粉样蛋白的进化,这可能通过衰老中的拮抗多效性机制导致脂联素自相矛盾,导致AD。因此,通过抑制脂联素信号传导来防止脂联素悖论可能证明对AD具有治疗作用。

更新日期:2020-07-03
down
wechat
bug